Study S001163

Exenatide (Byetta ®) Regulation of Intestinal and Hepatic Lipoprotein Particle Production in Humans.

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT01056549
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Masking: SINGLE
Status: COMPLETED
Enrollment: 15
Start: 2010-01
Primary completion: 2011-09
Lead sponsor: University Health Network, Toronto
Conditions: Hyperlipidemia
Interventions: DRUG:exenatide
Results posted: FALSE

Registered primary outcomes

The objective is to examine the change in apoB48 production rate after one subcutaneous injection of exenatide, under conditions of a pancreatic clamp and a steady state fed state. [over 10 hours]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0012548	Exenatide, a glucagon-like peptide-1 receptor agonist, acutely inhibits intestinal lipoprotein production in healthy humans. Xiao C, Arteriosclerosis, thrombosis, and vascular biology	2012	Randomized trial	PMID 22492091 DOI	cites ClinicalTrials.gov:NCT01056549; registry reference DERIVED:22492091